Patents by Inventor Ignacio MORAGA

Ignacio MORAGA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of producing Th9 T-cells
    Patent number: 12187771
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: January 7, 2025
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • Method of producing th9 t-cells
    Publication number: 20210188932
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Application
    Filed: August 7, 2020
    Publication date: June 24, 2021
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
    Patent number: 10738096
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: August 11, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • SUPERKINES AND SYNTHEKINES: REPURPOSED CYTOKINES WITH NEW AND ENHANCED SIGNALING ACTIVITIES
    Publication number: 20180016316
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Application
    Filed: July 27, 2017
    Publication date: January 18, 2018
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
    Patent number: 9738696
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: August 22, 2017
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: K. Christopher Garcia, Darren L. Bates, Ignacio Moraga
  • SUPERKINES AND SYNTHEKINES: REPURPOSED CYTOKINES WITH NEW AND ENHANCED SIGNALING ACTIVITIES
    Publication number: 20160244499
    Abstract: Disclosed herein are IL-4 cytokine compositions with enhanced biological activity having increased selectivity for IL-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (IL-4) muteins. The disclosed methods encompass administering an IL-4 to treat neoplastic diseases, autoimmune diseases, infectious diseases or for expanding a hematopoietic cell population.
    Type: Application
    Filed: August 8, 2013
    Publication date: August 25, 2016
    Inventors: K. Christopher GARCIA, Darren L. BATES, Ignacio MORAGA